Angiogenesis-based therapies for the skin diseases include both angiogenesis inhibitors and angiogenesis stimulating drugs:

• Antiangiogenic drugs are being developed to inhibit new blood vessel growth in cutaneous malignancies and psoriasis. A number of angiogenic skin conditions, such as rosacea and psoriasis, are already being treated with drugs known to be angiogenesis inhibitors (minocycline, vitamin D3 analogs).

• Angiogenesis-stimulating drugs (growth factor peptides ) and devices (bioengineered living skin equivalents) are being developed to promote new blood vessel growth to accelerate wound healing.